DexCom (DXCM) Releases Preliminary, Unaudited Results for Q4 2025

DexCom, Inc. (NASDAQ:DXCM) is one of the Best Fundamental Stocks to Buy According to Analysts. On January 12, the company released its preliminary, unaudited results for Q4 2025, with total revenue coming at ~$1.260 billion, reflecting an increase of 13% YoY. Notably, the US revenue is projected to be ~$892 million, demonstrating 11% growth compared to Q4 2024.

DexCom, Inc. (NASDAQ:DXCM) ended 2025 on a healthy note, with revenue surpassing the high-end of its guidance and the initial launch of its latest sensor technology with the G7 15 Day system. Since clinical momentum continues to build throughout the CGM category, DexCom, Inc. (NASDAQ:DXCM) is looking forward to extending its growth runway through continued innovation as well as evidence generation in 2026.

For 2026, DexCom, Inc. (NASDAQ:DXCM) expects total revenue of between $5.16 billion – $5.25 billion, exhibiting expected growth of ~11%-13% over 2025. Notably, this outlook takes into consideration the sensor volume growth because of increasing CGM awareness for people with diabetes, the rollout of Stelo, further international expansion, and broader market dynamics.

DexCom, Inc. (NASDAQ:DXCM) is a medical device company, which focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems.

While we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.